Biotechnology company Amgen will pay $24.9 million in a settlement over whistleblower allegations that the company paid kickbacks to long-term care pharmacies to increase the use of an anemia drug in nursing homes.
MDI Achieve announced that MatrixCare is now integrated with several leading pharmacy service firms. These include Omnicare, PharMerica, and FrameworkLTC.
With more vendors targeting the hospice market, two drug giants appear ready to face off. Walgreens left the institutional-pharmacy business in 2010, of which hospice pharmacy is a part, in a deal with Omnicare. Walgreens traded the unit for Omnicare's home-infusion business. Since then, Omnicare has been the market leader for hospice drugs. So why the strategy change for Walgreens?
The parent company of Golden Living officially launched AlixaRx with predictions it could become a $250 million per year business within 18 months.
Executives tied to one of the nation's largest nursing home chains say a new institutional pharmacy model they unveiled this week could soon become the market's No. 3 player. The parent group of Golden Living officially launched AlixaRx this week with predictions it could become a $250 million per year business within 18 months.
The headlines were big. Really big. And they involved a long-term care corporate giant settling yet another lawsuit. But they didn't tell the story I really wanted to know about. And that you probably want to know about, too.
Omnicare agreed to settle over claims it provided a kickback when it bought Total Pharmacy services LLC in 2004. Terms of the deal were not released.
Long-term care pharmacy provider Omnicare has agreed to pay the government $50 million to settle charges that it illegally dispensed controlled medications to long-term care residents.
Omnicare has officially ended its attempt to absorb PharMerica Corp. The reversal comes less than a month after federal regulators attempted to block the deal. Officials said the merger would have created an institutional pharmacy company that reaches nearly 60% of the nation's nursing home beds. PharMerica has repeatedly tried to prevent the takeover since it was announced last year. PharMerica countered that the offer was insufficient and was unlikely to survive antitrust scrutiny.
Leading long-term care pharmacy provider Omnicare, which announced this week that it has ended its efforts to takeover competitor PharMerica, posted a profit in the fourth quarter.
Omnicare announced Monday that it is extending its offer to purchase all outstanding shares of rival PharMerica for $15 per share to Jan. 20. The original offer was scheduled to expire Dec. 2.
Maryland and North Carolina are among several states set to receive a portion of the settlement stemming from a nursing home company kickback case.
A proposed regulation that would require nursing homes to hire independent pharmacists to oversee residents' medication plan regimens could have a huge impact on pharmacy services suppliers such as Omnicare and PharMerica.
Omnicare has filed a lawsuit in hopes of making PharMerica accept a $440 million purchase offer and halt a poison pill anti-takeover defense.
Omnicare's top management decided private negotiations with their counterparts at takeover target PharMerica were not working. So on Tuesday, Omnicare went public with an announced $15 per share bid for the company. The proposed deal would involve the No. 1 institutional pharmacy provider purchasing the No. 2 for $715 million, according to an Omnicare announcement.
Omnicare, the biggest institutional pharmacy provider in the long-term care sector, publicly announced a $715 million bid for top rival PharMerica on Tuesday. Dissatisfied with the outcome of behind-doors talks over the past four months, Omnicare leaders decided to take their case directly to PharMerica board members.
Mariner Health Care Inc. and SavaSenior Care have agreed to pay $14 million to the U.S. in the latest development in the Omnicare pharmacy kickback scandal, according to new reports.
Long-term care pharmacy giant Omnicare has agreed to pay a $98 million settlement in connection with allegations it engaged in an illegal kickback scheme with drug maker Ivax, the U.S. Department of Justice announced Tuesday.